[CAS NO. 259793-96-9] Favipiravir

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [259793-96-9]

Catalog

HY-14768

Brand

MCE

CAS

259793-96-9

DESCRIPTION [259793-96-9]

Overview

MDL	-
Molecular Weight	157.10
Molecular Formula	C5H4FN3O2
SMILES	O=C(N)C1=NC(F)=CNC1=O

For research use only. We do not sell to patients.

29 Publications Citing Use of MCE

Summary

Favipiravir (T-705) is a potent viral RNA polymerase inhibitor, it is phosphoribosylated by cellular enzymes to its active form, Favipiravir-ribofuranosyl-5′-triphosphate (RTP). Favipiravir-RTP inhibits the influenza viral RNA-dependent RNA polymerase ( RdRP ) activity with an IC ₅₀ of 341 nM.

IC50 & Target

IC50: 341 nM (RdRP) ^[1]

In Vitro

Favipiravir (T 705) is an antiviral drug that selectively inhibits the RNA-dependent RNA polymerase of influenza virus. Favipiravir (T 705) is a novel antiviral compound that selectively and potently inhibits the RNA-dependent RNA polymerase (RdRP) of influenza and many other RNA viruses. Favipiravir-RTP does not inhibit the human DNA polymerase α, β or γ with IC ₅₀ >1 mM. The IC ₅₀ for the human RNA polymerase II is 905 μM; Favipiravir is therefore 2,650 times more selective for the influenza virus RdRP, consistent with the lack of inhibition of host-cell DNA and RNA synthesis ^[1] . Favipiravir (T 705) acts as a pro-drug, its cytotoxicity is expected to be cell-line dependent. Favipiravir inhibits in a dose-dependent manner MNV-induced CPE (EC ₅₀ : 250±11 μM) and MNV RNA synthesis in cell culture (EC ₅₀ :124±42 μM). Despite this rather modest antiviral activity, Favipiravir (T 705) is able to completely inhibit norovirus replication at a concentration of 100 μg/mL, which is a concentration that has little or no adverse effect on the host cell (cell viability >80%) ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Favipiravir (T 705) (30 mg/kg/day, orally) improves survival compare to placebo. Favipiravir (T 705) also provides significant protection against the A/Duck/MN/1525/81(H5N1) virus at a dose of 33 mg/kg/day or more, regardless of the number of daily doses. When given 4 times a day, all mice survive ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01068912	MDVI, LLC	Influenza	February 2010	Phase 2
NCT04319900	Beijing Chao Yang Hospital	Novel Coronavirus Pnuemonia	March 5, 2020	Phase 2\|Phase 3
NCT02026349	MDVI, LLC\|MediVector, Inc.	Influenza	January 2014	Phase 3
NCT04387760	Royal College of Surgeons in Ireland - Medical University of Bahrain\|Ebrahim Khalil Kanoo Community Medical Center\|Hereditary blood Disorder Centre - Salmaniya Medical Complex\|Mohammed Bin Khalifa Bin Sulman Al Khalifa Cardiac Centre, Awali\|Jidhafs COVID-19 Centre\|Sitra FICU\|Salmaniya Medical Complex- 6th Floor\|Salmaniya Medical Complex- Helipad	SARS-CoV 2\|COVID-19	August 11, 2020	Phase 2
NCT04445467	Bayside Health	COVID	July 30, 2020	Phase 2
NCT04448119	Appili Therapeutics Inc.\|MOUNT SINAI HOSPITAL\|Applied Health Research Centre\|Sunnybrook Health Sciences Centre\|University Health Network, Toronto\|University of Toronto	COVID-19\|SARS-CoV-2	October 16, 2020	Phase 2
NCT01728753	MDVI, LLC\|United States Department of Defense	Influenza	November 2012	Phase 1\|Phase 2
NCT04333589	Peking University First Hospital	COVID-19	April 1, 2020	Not Applicable
NCT04376814	Baqiyatallah Medical Sciences University	COVID-19\|Favipiravir\|Kaletra\|Hydroxychloroquine\|Lopinavir+Ritonavir	March 29, 2020	Not Applicable
NCT04532931	Shin Poong Pharmaceutical Co. Ltd.\|Medicines for Malaria Venture	COVID-19	September 3, 2020	Phase 2
NCT04542694	Promomed, LLC	COVID-19	May 21, 2020	Phase 3
NCT04600895	Appili Therapeutics Inc.	Covid19	November 30, 2020	Phase 3
NCT02662855	Beijing Institute of Pharmacology and Toxicology\|Beijing 302 Hospital\|307 Hospital of PLA\|Sierra Leone-China Friendship Hospital\|Centers for Disease Control and Prevention, China	Ebola Virus Disease	November 2014	Phase 2
NCT05502081	Mansoura University Hospital	COVID-19	November 1, 2021	Phase 4
NCT04746183	University of Liverpool\|University of Southampton\|Liverpool School of Tropical Medicine\|Liverpool University Hospitals NHS Foundation Trust\|University of Cambridge	Covid19	July 3, 2020	Phase 1\|Phase 2
NCT04727775	Astana Medical University	Complication of Medical Care\|Pneumonia, Viral	December 1, 2020
NCT04940871	University of Pecs\|Hungarian Ministry of Innovation and Technology	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)	November 25, 2021	Phase 2
NCT04718285	Bahçe?ehir University\|Medipol University\|The Scientific and Technological Research Council of Turkey	COVID-19\|SARS-CoV-2	May 15, 2021	Phase 2
NCT04407000	World Medicine ILAC SAN. ve TIC. A.S.\|Novagenix Bioanalytical Drug R&D Center\|Farmagen Ar-Ge Biyot. Ltd. Sti	Bioequivalence	June 23, 2020	Phase 1
NCT04475991	Hospital General de México Dr. Eduardo Liceaga\|CCINSHAE. Secretaría de Salud. México\|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran\|Centro de Investigación en. Enfermedades Infecciosas, Mexico	COVID-19	July 13, 2021	Phase 2
NCT04373733	Chelsea and Westminster NHS Foundation Trust\|NEAT ID Foundation\|FUJIFILM Toyama Chemical Co., Ltd.\|Imperial College London	Coronavirus Infection	May 1, 2020	Phase 3
NCT04828564	The Scientific and Technological Research Council of Turkey\|Ankara City Hospital Bilkent\|Istanbul Umraniye Training and Research Hospital\|Koç University\|Monitor CRO	SARS-CoV2\|COVID-19	April 2021	Phase 2\|Phase 3
NCT04349241	Ain Shams University	Coronavirus Disease (COVID-19)	April 18, 2020	Phase 3
NCT04402203	Bangladesh Medical Research Council (BMRC)	COVID-19\|Favipiravir (Favipira)	May 2020	Phase 2\|Phase 3
NCT04351295	Tanta University	COVID	April 20, 2020	Phase 2\|Phase 3
NCT04474457	Ministry of Health, Turkey\|Hacettepe University, School of Medicine\|Prof. Dr. Cemil Tasc?oglu City Hospital\|Umraniye Training and Research Hospital\|Istanbul Training and Research Hospital\|Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey\|Tepecik Training and Research Hospital\|Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine\|Ankara University\|Ankara City Hospital Bilkent\|Ankara Training and Research Hospital\|Ege University Hospital (Application and Research Center)\|Derince Training and Research Hospital\|Istanbul University\|Kayseri City Hospital	COVID-19	June 11, 2020
NCT04558463	Indonesia University	Covid19	April 16, 2020	Phase 3
NCT04907682	Bernhard Nocht Institute for Tropical Medicine\|University of Hamburg-Eppendorf\|Alliance for International Medical Action\|Institut National de la Santé Et de la Recherche Médicale, France\|University of Bordeaux\|Federal Medical Centre, Owo\|Irrua Specialist Teaching Hospital	Lassa Fever	July 30, 2021	Phase 2
NCT05041907	University of Oxford	COVID-19	September 30, 2021	Phase 2
NCT05185284	Promomed, LLC\|Solyur Pharmaceuticals Group	COVID-19	August 11, 2021	Phase 3
NCT04981379	Health Institutes of Turkey	Covid19	November 16, 2020	Phase 3
NCT04784559	PharmaMar	COVID-19 Infection	June 4, 2021	Phase 3
NCT04392973	King Abdullah International Medical Research Center	COVID19	May 21, 2020	Not Applicable
NCT04434248	Chromis LLC\|Chemical Diversity Research Institute	COVID-19	April 23, 2020	Phase 2\|Phase 3
NCT02739477	Institut National de la Santé Et de la Recherche Médicale, France	Ebola Virus Survivor	April 2016	Phase 2
NCT04464408	King Abdullah International Medical Research Center\|Ministry of Health, Saudi Arabia	COVID-19	July 23, 2020	Phase 2\|Phase 3
NCT04818320	Penang Hospital, Malaysia\|Enche´ Besar Hajjah Khalsom Hospital\|Jasin Hospital\|Kepala Batas Hospital\|Melaka Hospital\|Permai Hospital\|The Queen Elizabeth Hospital\|Raja Perempuan Zainab II Hospital\|Raja Permaisuri Bainun Hospital\|Sultanah Aminah Hospital\|Sultanah Nur Zahirah Hospital\|Sungai Buloh Hospital\|Tampin Hospital\|Tengku Ampuan Afzan Hospital\|Tuanku Fauziah Hospital\|Tuanku Jaafar Hospital\|Tumpat Hospital\|Institute for Clinical Research\|Tawau Hospital\|Hulu Terrengganu Hospital	Covid19	February 16, 2021	Phase 3
NCT04411433	Ministry of Health, Turkey\|Hacettepe University, Faculty of Medicine\|Prof. Dr. Cemil Tasc?oglu Education and Research Hospital Organization\|Umraniye Education and Research Hospital\|SB Istanbul Education and Research Hospital\|Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey\|Tepecik Training and Research Hospital\|Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine\|Ankara University\|Ankara City Hospital Bilkent\|Ankara Training and Research Hospital\|Ege University Hospital (Application and Research Center)\|Kocaeli Derince Education and Research Hospital\|Istanbul University\|Kayseri City Hospital	Sars-CoV2\|COVID-19	May 8, 2020	Phase 3
NCT05279235	Shanghai Vinnerna Biosciences Co., Ltd.\|Sponsor GmbH	Moderate to Severe COVID-19	March 8, 2022	Phase 3
NCT03394209	Capital Medical University\|Beijing Institute of Pharmacology and Toxicology\|University of Oxford\|Centers for Disease Control and Prevention, China	Influenza, Human\|Critical Illness\|Influenza	February 6, 2018	Phase 2
NCT04310228	Peking University First Hospital	COVID-19	March 8, 2020	Not Applicable
NCT04600999	University of Pecs\|HECRIN Consortium\|Hungarian Ministry of Innovation and Technology	SARS-CoV-2 Infection	October 7, 2020	Phase 3
NCT02329054	Institut National de la Santé Et de la Recherche Médicale, France	Ebola Virus Disease	December 2014	Phase 2
NCT05014373	University of the Philippines\|Department of Health, Philippines	Covid19	October 12, 2020	Phase 3
NCT04346628	Stanford University	Sars-CoV2\|COVID-19	July 12, 2020	Phase 2
NCT04336904	Giuliano Rizzardini\|ASST Fatebenefratelli Sacco	COVID-19	March 25, 2020	Phase 3
NCT04358549	Fujifilm Pharmaceuticals U.S.A., Inc.	COVID-19	April 17, 2020	Phase 2
NCT01419457	MDVI, LLC	Healthy\|Hepatic Impairment	August 2011	Phase 1
NCT04425460	Zhejiang Hisun Pharmaceutical Co. Ltd.\|Opera CRO, a TIGERMED Group Company	COVID-19	June 2020	Phase 3
NCT05417997	RAAS Nutritionals, LLC\|Kayseri City Hospital	COVID-19 Respiratory Infection\|FLU\|Cold; Influenza\|Bacterial Pneumonia\|COVID-19 Pneumonia	May 29, 2021	Phase 3
NCT04918927	Coordinación de Investigación en Salud, Mexico\|University College, London\|Centro de Investigacion y Estudios Avanzados del Instituto Politecnico Nacional (CINVESTAV)\|Universidad Autonoma de Guadalajara\|Siegfried Rhein S.A. de C.V.\|Strides Pharma Science Limited\|Hakken Enterprise	Covid19	October 12, 2021	Phase 2
NCT04613271	Ina-Respond\|Center for Research and Development of Health Resources and Services, National Institute of Health Research and Development (NIHRD), Indonesia	Infectious Disease\|SARS-CoV Infection\|Covid19	October 15, 2020	Phase 3
NCT04499677	University College, London\|LifeArc	COVID-19	September 24, 2020	Phase 2
NCT02008344	MDVI, LLC\|MediVector, Inc.	Influenza	December 2013	Phase 3
NCT04694612	Nepal Health Research Council	Covid19	January 1, 2021	Phase 3
NCT04501783	R-Pharm	COVID-19	May 20, 2020	Phase 3
NCT04359615	Shahid Beheshti University of Medical Sciences	COVID-19	April 20, 2020	Phase 4

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 636.54 mM ; Need ultrasonic)

H ₂ O : 6.25 mg/mL ( 39.78 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	6.3654 mL	31.8269 mL	63.6537 mL
5 mM	1.2731 mL	6.3654 mL	12.7307 mL
10 mM	0.6365 mL	3.1827 mL	6.3654 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 4.55 mg/mL (28.96 mM); Clear solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (15.91 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (15.91 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (15.91 mM); Clear solution
5.

Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline

Solubility: ≥ 2.5 mg/mL (15.91 mM); Clear solution
6.

Add each solvent one by one: 5% DMSO >> 95% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (15.91 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

2-Pyrazinecarboxamide, 6-fluoro-3,4-dihydro-3-oxo-

Pyrazinecarboxamide, 6-fluoro-3,4-dihydro-3-oxo-

6-Fluoro-3,4-dihydro-3-oxo-2-pyrazinecarboxamide

6-Fluoro-3-hydroxy-2-pyrazinecarboxamide

T 705

T 705 (pharmaceutical)

Favipiravir

Avigan

Favilavir

FabiFlu